Drug interaction study for new lung cancer therapy
Part of Cancer clinical trials.
This trial tests a new drug (HS-10504) to see how it affects another medicine called midazolam (used for sedation). The goal is to understand how HS-10504 is processed in the body, which may help in future dosing. Participation may provide access to a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with non-small cell lung cancer that has spread or cannot be removed by surgery.
- Your tumor has a specific genetic change called an EGFR mutation.
- You have previously taken a third-generation EGFR TKI medicine (like osimertinib/Tagrisso) and it stopped working or caused too many side effects.
- You are physically able to handle daily activities (performance status 0 or 1).
- You are not taking certain medications that could interact with the study drugs.
- You have no significant heart problems, such as an irregular heartbeat or heart failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HSK40118, for people with advanced non-small cell lung cancer (NSCLC) that has an EGFR mutation and has been treated with certain EGFR-targeted therapies before. The goal is to see if this drug can help when other treatments stop working.
This trial tests a new study drug (HS-10504) given along with other treatments for advanced non-small cell lung cancer that has not responded to earlier therapy. The goal is to see if adding this drug can help control the cancer and shrink tumors.
This trial tests a new targeted drug (HS-10504) for people with advanced EGFR-mutated non-small cell lung cancer that has worsened after previous EGFR inhibitor therapy. The study aims to see if this drug can help shrink tumors or slow cancer growth.
This Phase 1/2 trial tests HS-10375, a study drug, in people with advanced or metastatic non-small-cell lung cancer (NSCLC) whose cancer has a specific EGFR mutation (C797S). It may help by targeting that mutation when standard treatments are not an option.
This trial tests a new drug called HS-10370 combined with other anti-cancer treatments for people with advanced lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if this combination can shrink or control tumors better than other options.
This trial tests a new pill (HS-10504) compared with standard chemotherapy for people with advanced non-small cell lung cancer that has a specific genetic change called C797S and has already been treated with an EGFR inhibitor. The goal is to see if the new drug works better at shrinking or controlling the cancer.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.